Sept. 8, 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test. The partnership will bring Shield to more than 250 hospitals and health systems and more than 15,000 PathGroup-affiliated physicians across 25 states. PathGroup is integrating Shield into its electronic ordering systems across its health system partners. In addition, PathGroup’s digitally enabled histopathology lab and physician team will provide expertise in performing immunohistochemistry testing for Guardant. Guardant’s IHC test suite provides comprehensive testing for key biomarkers in all solid tumors, such as lung, breast, gastric, and ovarian cancers.
Shield is a noninvasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for people at average risk for the disease, age 45 or older. It is not intended for people at high risk for colorectal cancer.